Beijing Chunlizhengda Medical Instruments Co Ltd

Chunli Medical announced on August 28 that it plans to distribute a cash dividend of 1.3 yuan, tax included, for every 10 shares to all shareholders, with an estimated total payout of 49.68 million yuan, accounting for 41.42% of net profit attributable to the parent company. In the first half of 2026, the company achieved revenue of 417 million yuan and net profit attributable to the parent company of 120 million yuan.

Chunli Medical released its 2026 half-year report. Net profit attributable to the parent in the first half was 120 million yuan, up 4.8% year on year, but operating revenue was 417 million yuan, down 14.5% year on year. Net profit attributable to the parent after deducting non-recurring items was 114 million yuan, up 7.5% year on year. Net operating cash flow was 34.32 million yuan, down 75.7% year on year, and earnings per share were 0.3127 yuan. In the second quarter, operating revenue was 200 million yuan, down 22.4% year on year, and net profit attributable to the parent was 58.25 million yuan, up 3.3% year on year. As of the end of the second quarter, total assets were 3.591 billion yuan, down 1.9% from the end of the previous year, and net assets attributable to the parent were 3.048 billion yuan, up 2.1% from the end of the previous year. The company said its main business is the research, development, production and sales of implantable orthopaedic medical devices. Although operating revenue declined due to the market environment and policy impacts, it achieved steady growth in net profit by optimising its product structure and strengthening its market strategy, and made important progress in 3D printing and biomedical materials.

Chunli Medical disclosed its interim report on August 28. In the first half of 2026, it achieved operating revenue of 417 million yuan, down 14.46% year on year. Net profit attributable to shareholders of the listed company was 120 million yuan, up 4.79% year on year. Basic earnings per share were 0.31 yuan. The company plans to distribute a cash dividend of 1.3 yuan, tax included, for every 10 shares. During the reporting period, revenue declined due to the pace of orthopedic centralized procurement implementation and phased market factors at home and abroad. However, the company achieved steady profit growth through measures such as continuously ensuring stable supply of centralized procurement products, optimizing its product and market structure, and strengthening the competitiveness of its core business.